Download Medical Notes on Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2019 Medical Notes

About This Presentation

Description:The Evaluate Vantage Half-Year Review 2019 throws light on the most significant trends across pharma, medtech and biotech in the first half of 2019. The report talks about Mega-deals masking a significant decline in M&A activity for pharma and medtech, Bristol-Myers Squibb’s $74bn pending purchase of Celgene, Abbvie’s $63bn acquisition of Allergan, positioning 2019 to be a record year for pharma M&A spend, Verily’s $1bn round of funding in Q1, slowdown in the total number of M&A deals in both pharma and medtech, investors being cautious due to potential US drug reforms, etc.

Tags:Pharma, Biotech, Medtech, pharmaceutical, biopharma, Pharmaceutical Industry, report on pharmaceutical industry, US drug reforms

Published on: Jun 29, 2020 | Views : 1826 | Downloads : 0

Comment

Transcript

No transcript available for this presentation

User Presentation
Related Presentations

Covid-19 Outbreak & Business Continuity - 4 Practical Recommendations

About : An experienced pharma professional managing sales, marketing and brand management of top global pharma products Presently leading a team of experts in the development and execution of pharma eCommerce strategies that support GSK products to HCP customers.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : United States of America
Website :

Covid-19 Outbreak & Business Continuity - 4 Practical Recommendations

2020 US and global life sciences outlook

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2019

The History of Managed Care Organizations in the United States

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 - Booklet 4

Pharma 2020 Taxing times ahead

Electrolyte Disorders

A Review of Neuropharmacological Screening Techniques for Pharmaceuticals

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Orphan Drugs in the United States - Exclusivity, Pricing and Treated Populations

HEALTH A TO Z